Table 1.
Baseline characteristics
| Baseline Characteristics | Intervention, n=31 | Control, n=33 | Total, n=64 |
|---|---|---|---|
| Recipient | |||
| Age, yr | |||
| Mean ± SD | 11.03±4.05 | 10.65±4.31 | 10.83±4.16 |
| Range [minimum to maximum] | [1.58–16.17] | [1.75–16.42] | [1.58–16.42] |
| Sex (girls) | 13 (41.9%) | 14 (42.4%) | 27 (42.2%) |
| EBV-IgG positivity | 18 (58.1%) | 17 (51.5%) | 35 (54.7%) |
| CMV-IgG positivity | 12 (38.7%) | 11 (33.3%) | 23 (35.9%) |
| CMV high-risk constellationa | 10 (32.3%) | 9 (27.3%) | 19 (29.7%) |
| CMV prophylaxis | 12 (38.7%) | 12 (36.4%) | 24 (37.5%) |
| Donor | |||
| Age, yr | |||
| Mean ± SD | 22.69±17.06 | 24.22±19.52 | 23.48±18.24 |
| Range [minimum to maximum] | [0–50] | [0–53] | [0–53] |
| Sex (women) | 16 (51.6%) | 14 (42.4%) | 30 (46.9%) |
| CMV-IgG positivity | 19 (61.3%) | 15 (45.5%) | 34 (53.1%) |
| Graft ischemia time, h | |||
| Mean ± SD | 11.48±5.53 | 11.50±7.29 | 11.49±6.45 |
| Range [minimum to maximum] | [1.83–21.75] | [2.27–27.50] | [1.83–27.50] |
| Living donor | 5 (16.1%) | 10 (30.3%) | 15 (23.4%) |
| Study site | |||
| Site 1 | 27 (87.1%) | 28 (84.8%) | 55 (85.9%) |
| Site 2 | 2 (6.5%) | 1 (3.0%) | 3 (4.7%) |
| Site 3 | 2 (6.5%) | 3 (9.1%) | 5 (7.8%) |
| Site 4 | 0 (0.0%) | 1 (3.0%) | 1 (1.6%) |
| Race | |||
| White | 24 (77.4%) | 33 (100.0%) | 57 (89.1%) |
| Asian | 7 (22.6%) | 0 (0.0%) | 7 (10.9%) |
| Etiology of kidney disease | |||
| CAKUT | 9 (29.0%) | 11 (33.3%) | 20 (31.3%) |
| ARPKD | 2 (6.5%) | 2 (6.1%) | 4 (6.3%) |
| Nephronophthisis | 8 (25.8%) | 4 (12.1%) | 12 (18.8%) |
| Nephropathic cystinosis | 2 (6.5%) | 3 (9.1%) | 5 (7.8%) |
| FSGS | 2 (6.5%) | 3 (9.1%) | 5 (7.8%) |
| HUS | 2 (6.5%) | 3 (9.1%) | 5 (7.8%) |
| Congenital nephrotic syndrome | 1 (3.2%) | 2 (6.1%) | 3 (4.7%) |
| Unknown origin | 1 (3.2%) | 0 (0.0%) | 1 (1.6%) |
| Other | 4 (12.9%) | 5 (15.2%) | 9 (14.1%) |
| HLA mismatches at locus A | |||
| 0 | 12 (38.7%) | 9 (27.3%) | 21 (32.8%) |
| 1 | 16 (51.6%) | 18 (54.6%) | 34 (53.1%) |
| 2 | 3 (9.7%) | 6 (18.2%) | 9 (14.1%) |
| HLA mismatches at locus B | |||
| 0 | 6 (19.4%) | 4 (12.1%) | 10 (15.6%) |
| 1 | 11 (35.5%) | 18 (54.6%) | 29 (45.3%) |
| 2 | 14 (45.2%) | 11 (33.3%) | 25 (39.1%) |
| HLA mismatches at locus DR | |||
| 0 | 9 (29.0%) | 9 (27.3%) | 18 (28.1%) |
| 1 | 16 (51.6%) | 20 (60.6%) | 36 (56.3%) |
| 2 | 6 (19.4%) | 4 (12.1%) | 10 (15.6%) |
CAKUT, congenital anomalies of the kidney and urinary tract; ARPKD, autosomal recessive polycystic kidney disease; HUS, hemolytic uremic syndrome.
a
CMV-IgG–negative recipient with CMV-IgG–positive donor.